Stifel upgraded Edwards Lifesciences (EW) to Buy from Hold with a price target of $90, up from $75. The firm said the upgrade is predicated on “now more credible TAVR growth re-acceleration potential.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW: